• UUUU will pay off half of its debt in July, plans to be debt free by the end of 2020
• Expects to save about $350,000 in avoided interest
• Energy Fuels has focused on strategy to eliminate debt over the past several years with minimal impact to shareholders

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest uranium mining company in the United States, plans to take a significant step forward in its strategy to reduce debt and further strengthen its balance sheet by redeeming half of its outstanding debt earlier than planned (http://ibn.fm/eAj5w). The company notified holders of the outstanding floating rate convertible unsecured subordinated debentures of its plans earlier this month.

“Energy Fuels is proud to announce that we are paying off half of our debt on July 14, 2020, and that we expect to become debt-free by the end of 2020,” said Energy Fuels president and CEO Mark S. Chalmers. “We are proactively managing our remaining debt to ensure we have the ability to pay it off on our own timing and terms and with minimal disruption. We believe it makes sense to redeem half of the Debentures now because the U.S.-Canada exchange rate is favorable, we have sufficient cash available, and we will avoid approximately US$350,000 in interest payments in 2020 by doing so. We will address the remaining Cdn$10,430,000 balance over the next several months when we think the timing is most appropriate.”

On July 14, 2020, UUUU will redeem the principal amount of Cdn$10,430,000, half of the outstanding Cdn$20,860,000 debentures, originally due Dec. 31, 2020. The debentures are redeemable for an amount equal to 101% of the principal due, plus accrued and unpaid interest thereon, up to but excluding the redemption date.

The plan calls for the debentures to be redeemed on a pro rata basis to the nearest multiple of Cdn$1,000 in accordance with the principal amount of the debentures registered in the name of each holder, or in such other manner as deemed equitable, subject to any applicable regulatory approvals. The record date for determining the holders of the debentures to be redeemed is slated for July 8, 2020. Following the partial redemption, Cdn$10,430,000 aggregate principal amount of the debentures will remain outstanding and shall continue to be subject to the terms of the indenture and remain listed on the Toronto Stock Exchange.

“Many junior uranium producers and developers in North America are currently incurring significant amounts of debt to fund exploration and development activities and to cover corporate overheads,” Chalmers said. “However, without sufficient cash flow, servicing this debt can become extremely burdensome and destructive to shareholder value. Instead, Energy Fuels has focused on a strategy to reduce our debt load over the past several years, including paying off our debt to the State of Wyoming in 2018, all with minimal impact to our shareholders. Furthermore, we do not expect to incur more debt in the future without a clear, short-term path toward positive cash flow. We will continue to manage all aspects of our business proactively, including maintaining our position as the leading U.S. uranium producer, advancing our exciting rare earth initiatives, and maintaining the other significant aspects of our business plan, including our significant inventories of uranium and vanadium.”

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (“ISR”) project in Wyoming, the Alta Mesa ISR Project in Texas, and the White Mesa Mill in Utah — the only conventional uranium mill operating in the U.S. today with a licensed capacity of more than 8 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, and production capacity than any other producer, Energy Fuels is in a unique position to take charge as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry. Energy Fuels is also making significant progress in entering the U.S. rare earth processing business.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• InsuraGuest partners with hospitality expert Adam Gatto to increase hospitality footprint
• InsuraGuest’s Hospitality Liability policy ideal for vacation-rental operators
• Mammoth market: vacation rental companies number 23,000 in U.S.; 115,000 globally

In the hospitality business, it’s not who you know but who knows you, which is why the partnership between InsuraGuest Technologies (TSX.V: ISGI) and hospitality and hotel expert Adam Gatto is a big deal. Gatto heads AAG Capital Management (“AAG”), which has been involved with single-asset and portfolio sales of select-service hotels, large convention hotels, and hotel development. Joining forces with Gatto should expand InsuraGuest’s presence in new markets (http://ibn.fm/TIF1h).

InsuraGuest is a pioneer in the fast-developing insurtech sector of digitized insurance products that reduce operating costs and increase customer satisfaction. The company has already launched a hospitality policy that offers hotel owners and vacation-rental operators a way to increase property revenue and decrease risk and claims profiles while protecting their guests. Now, ISGI is turning attention to other niches in the mammoth insurance marketplace; this impressive start-up could be the next Unicorn in the insurtech space.

In the same way fintech disrupted financial services, insurtech is revolutionizing the staid insurance industry. It’s an industry badly in need of disruption, with many of its practices and products outdated and change slow in coming. For example, some maritime contracts such as bottomry and respondentia date back to ancient Babylon, circa 2000 BCE, and yet were still quite common in the nineteenth century. The development of digital technologies has made the industry’s timeworn operations seem even more antiquated. But these technologies also provide ways to make insurance protection more accessible, affordable, and better tailored to individual needs.

Many corners of the insurance industry are ripe for reinvention. Some are already in upheaval, with upstart digitech insurance providers laying claim to niche after niche, sometimes with amazing results. One such provider, Lemonade, founded just five years ago, is now worth $2 billion – according to Forbes (http://ibn.fm/w2JwX) – after the company raised $300 million. The company uses behavioral economics, artificial intelligence, and chatbots to deliver renter’s and homeowner’s insurance policies at greatly reduced prices.

Another provider — Root Insurance — also targets homeowners. Root first ventured into the car insurance marketplace with a novel product that bases the policy premium on the motorist’s driving behavior. After its latest funding round in September 2019, the company was valued at $3.65 billion (http://ibn.fm/7Lyog). And Next Insurance, which offers general liability coverage to small business, is now the nation’s latest insurtech Unicorn, according to PitchBook, crossing $1 billion in valuation after reinsurance giant, Munich Re, ploughed $250 million into the start-up (http://ibn.fm/75A5j).

Munich Re’s investment in Next Insurance is not surprising. A major driver of demand for digitization has come from traditional carriers as they move to simplify transaction processes and improve customer service. These establishment insurers and brokers are turning to insurtech start-ups to help update their legacy systems and increase market responsiveness, reports a recent Boston Consulting Group (“BCG”) study. The reasons are obvious. Digitization is expected to significantly improve the insurance industry’s core business of risk measurement and management, which in turn should allow more consumers to enjoy basic insurance protections at less cost than is currently available.

InsuraGuest’s Hospitality product called Hospitality Liability offers coverages that protect hotels and vacation-rental properties, addressing covered claims from guests during their stays. The vacation-rental market looks particularly promising. In recent times, it has expanded by around 6.9%, a growth rate that tops regular hotel bookings. Market revenues are estimated to have reached $57.7 billion at the end of 2019, driven by the prodigious 115,000 vacation-rental companies operating globally, 23,000 of which are based in the United States. Undoubtedly, many of these companies will see InsuraGuest’s Hospitality Liability coverage as a way to add value to their offerings.

As insurtech continues to grow and disrupt the insurance industry, InsuraGuest Technologies has stepped into the insurtech/fintech space offering a tremendous amount of value with powerful new digital insurance products. That begs the question: could InsuraGuest Technologies be the next Unicorn to watch out for?

For more information, visit the company’s website at www.InsuraGuest.com.

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• App will allow company executives to monitor shareholders’ trading behavior from any location
• Platform enables diverse account management capabilities, including ability to build contact profiles on shareholders, track outstanding warrants and shares, manage social media & news campaigns remotely
• Online modes of connecting with investors have become especially relevant in wake of COVID-19 pandemic

SRAX (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, has recently launched a new app for its investor intelligence platform, Sequire. Sequire, which enables companies to monitor their shareholders’ buying and selling behavior and interact with them through a number of digital mediums, has seen a rapid gain in adherents following the onset of the COVID-19 pandemic, which has caused demand for virtual investor relations platforms and services to skyrocket. Now through the launch of its proprietary mobile application, Sequire will allow CEOs & CFOs of public companies to monitor their investors’ trading behaviors anywhere they go. The application, which is available to download for free on the App Store and Google Play, includes many of the features which have been popularized through the Company’s existing service. Subscribers will now be able to gain insights on their shareholder’s trading activity, analyze market-maker activity within their listed equities through the use of level 2 trading data and even turn real-time conference visitor data into targeted cross-channel ads. The app will also provide users with a business card scanner, enabling executives to quickly scan business cards to save and organize contact information from people they meet. “We are thrilled to launch the Sequire mobile app enabling our clients to now monitor their investors’ behaviors and their contributions anytime and anywhere,” says SRAX CEO and founder Christopher Miglino (http://ibn.fm/p5v1M). “We’ll also be launching more exciting mobile features in the next few months, so stay tuned.” Investor relations functions have increasingly gone digital as companies find themselves unable to meet with their investors in person. Hundreds of investor conferences across the world have been moved to virtual platforms while webinars have gained in popularity—the latter medium allowing presenters to target and reach far wider audiences than ever before. However the shift to digital mediums has been juxtaposed against record trading volumes and market volatility, with monthly equity transactions hitting historic highs across a multitude of global stock exchanges in the first quarter (http://ibn.fm/iUh0A). As investors have sought to gain greater clarity on corporate prospects during these uncertain times, virtual IR platforms such as SRAX Inc’s Sequire have found themselves in greater demand than ever before. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• In January 2020, Bullfrog completed a private placement of shares that raised C$2 million to fund drilling of its flagship project with 43-101 compliant gold resource of 525,000 ounces and 110,000 ounces of inferred resources within pit plans
• Company’s project is 125 northwest of Las Vegas and in the area where Barrick Bullfrog gold Inc. produced over 2.3 million ounces of gold between 1989 and 1999
• Bullfrog’s land position is now covers 5,250 acres in the prolific Bullfrog Gold District
• Average gold price is expected to reach by year end an all-time high of $1,970 per troy ounce

Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) President and CEO David Beling detailed the company’s strategic efforts to position for growth over the past decade and discussed development of its flagship Bullfrog Project, as well as company management in an exclusive audio interview with NetworkNewsWire.

“Bullfrog Gold took over an OTC-listed company in mid-2011. The key property that we had at that time is now our flagship property called The Bullfrog Project. We didn’t have any known ounces on it, but we had great potential in an area where Barrick Bullfrog Inc. produced 2.3 million ounces from 1989 to 1999,” Beling said (http://ibn.fm/n1E2s).

In the years since, Bullfrog has expanded its base in Bullfrog Gold District 125 miles northwest of Las Vegas, Nevada. The company has acquired more lands, including an option to purchase key lands from Barrick that contain most of the established resources. Their strategic land ownership and resources have positioned the company for success on the market, particularly with soaring gold prices. According to aggregated statistics, average gold prices worldwide are expected to reach an all-time high of $1,970 per troy ounce this year, from $1,390 per troy ounce in 2019. Analysts expect the average price to stay over $1,900 per ounce over the next few years (http://ibn.fm/90qY9).

Beling underlined that the company is committed to developing its Bullfrog project and adding value, having the necessary capability to take it into production or to complete an M&A or a corporate transaction on the property. “We just recently completed a 25-hole drill program to expand resources, further define expansions of the existing pits and initially test a new, highly prospective exploration target,” he said.

During the interview, Beling also detailed the company’s recent corporate achievements, including a Canadian Stock Exchange listing in September 2019 and closing a C$2 million (US$1.47 million) equity raise in mid-January 2020 to fund its recently completed Bullfrog Project drilling program.

Bullfrog’s corporate backing is just as impressive. The company’s management team has over a century of combined experience in the industry, Beling himself having been in the business for more than 55 years. Chairman and Director Alan Lindsay brings about 42 years of experience, 26 of which are in the mining industry, to the table, while Kjeld Thygesen, independent director, has 48 years of experience in mining research and investment management.

Additionally, approximately 5% of the company is owned by Owl Capital Corp., run by Ron Netolitzky and Dale Wallster. Netolitzky was inducted into the Canadian Mining Hall of Fame in 2015. Wallster and his team discovered what became Hathor’s Roughrider uranium deposit, sold to Rio Tinto for C$650 million (over US$479 million).

At present, the Bullfrog Project has a measured and indicated resource of 525,000,000 ounces of gold and 1.34 million ounces of silver at average grades of 1.02 and 2.61 grams per tonne within pit plans based on a gold price of $1,200 and a cutoff grade of 0.36 g/t. There is also an inferred in-pit resource of 110,000 ounces of gold and 248,000 ounces of silver at similar grades. Barrick conventionally milled and produced over 2.3 million ounces of gold and 2.49 million ounces of silver from three open pits and one underground mine between 1989 and 1999

Project lands cover the Bullfrog and Montgomery-Shoshone pits that the company intends to expand and process using low cost heap leaching methods. Several exploration targets are also planned for drilling. Since purchasing the initial land position in 2011, Bullfrog optioned 12 patents from Mojave Gold. The company also leased/optioned 28 claims and 6 patents from Barrick that include SE half of Montgomery-Shoshone pit and north third of Bullfrog deposit in 2015 and leased 24 patents, staked 134 claims, and purchased two patents during 2017 and 2018.

For more information, visit the company’s website at www.BullFrogGold.com.

NOTE TO INVESTORS: The latest news and updates relating to BFGC are available in the company’s newsroom at http://ibn.fm/BFGC

• Questions are being asked about key government agencies having sufficient funding, personnel and equipment to face upcoming hurricane season.
• CSU expert researchers predict an above-average Atlantic hurricane season in 2020.
• One of NSRI’s primary objectives is to provide solution for treatment, handling of tree debris, a frequent by-product of hurricanes.

As the Atlantic hurricane season officially begins, new concerns this year center on available funding and other resources available to the Federal Emergency Management Agency (“FEMA”). The season, already forecast to be an above-average hurricane this year, now raises questions about key government agencies having sufficient funding, personnel and equipment after significant resources have been diverted to fighting the novel coronavirus (http://ibn.fm/Tbn0e). National Storm Recovery Inc. (OTC: NSRI), a provider of storm/disaster recovery services, is prepared for the heavier-than-normal season, however, as its resources are focused on storm and disaster recovery rather than COVID-19.

“The Federal Emergency Management Agency (FEMA), often the first agency called when a major hurricane hits land, has already allocated considerable resources to fighting COVID-19,” reported an article published by The Hill. “According to an agency spokesperson, more than 3,100 FEMA employees have been tasked with combating the pandemic. As of April 30, FEMA had committed $5.4 billion to COVID-19 relief assistance from its disaster relief fund.”

The article goes on to note that FEMA’s disaster relief fund had been boosted to $45 billion this year, thanks to funding from a recent stimulus package, and that in its most recent report to Congress, FEMA stated that the fund had roughly $74.2 billion in it going into May.

However, “while $74 billion may seem like more than enough, a major hurricane could run the fund completely dry,” the article observed. “For reference, in 2017, Hurricane Harvey — a category 4 hurricane — did an estimated $125 billion in damage to Houston. In fact, FEMA allocated more than $6 billion in aid this fiscal year to continue the recovery process from 2017’s trio of deadly storms — Harvey, Maria and Irma.”

Earlier this year, researchers at Colorado State University predicted an above-average Atlantic hurricane season in 2020, citing the likely absence of El Niño as a primary factor (http://ibn.fm/2E0oK). The researchers observed that tropical and subtropical Atlantic sea surface temperatures are currently warmer than their long-term average values and are consequently also considered a factor favoring an active 2020 Atlantic hurricane season. The researchers also noted a 70% chance that a category 3, 4 or 5 hurricane would make landfall somewhere along the U.S. coastline this year.

“[The National Oceanic and Atmospheric Administration] NOAA’s Climate Prediction Center is forecasting a likely range of 13 to 19 named storms (winds of 39 mph or higher), of which 6 to 10 could become hurricanes (winds of 74 mph or higher), including 3 to 6 major hurricanes (category 3, 4 or 5; with winds of 111 mph or higher),” FEMA announced. “NOAA provides these ranges with a 70% confidence. An average hurricane season produces 12 named storms, of which 6 become hurricanes, including 3 major hurricanes.”

National Storm Recovery is prepared for the upcoming season. Through its subsidiaries, including National Storm Recovery LLC, NSRI provides tree services, debris hauling, removal and biomass recycling, manufacturing, packaging and sales of next-generation mulch products. One of the company’s primary corporate objectives is to provide a solution for the treatment and handling of tree debris, a frequent by-product of hurricanes. Historically such tree debris is sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation. NSRI is committed to creating synergistic and environmentally beneficial solutions to tree and storm waste disposal.

For more information, visit the company’s website at www.NationalArborCare.com.

NOTE TO INVESTORS: The latest news and updates relating to NSRI are available in the company’s newsroom at http://ibn.fm/NSRI

• Merger of Pressure BioSciences, SkinScience Labs and Cannaworx, Inc. is expected to close by June 30, 2020
• SkinScience Labs is the parent company of the award-winning Dr. Denese skin care and anti-aging product lines, a top QVC seller generating sales of over $500M since 2003
• The $3.5M order is for an initial four-month supply of SkinScience Labs’ (SSL)premium grade hand sanitizer
• Hand sanitizer market is growing exponentially; it is expected to reach $5.5 billion by 2024
• SkinScience Labs and Cannaworx product lines will leverage Pressure BioSciences’ proprietary Ultra Shear Technology (UST) for preparing high quality nanoemulsions to drive product quality and effectiveness, while reducing manufacturing cost

Pressure BioSciences (OTCQB: PBIO), a leader in the worldwide pressure technologies industry, announced that SkinScience Labs, a pending accretive acquisition of the Company, has received an initial $3.5 million order for its premium FDA-registered dermatological hand sanitizer product (http://ibn.fm/3UXmq).

SkinScience Labs (“SSL”) is the creator and parent company of award-winning Dr. Denese skin care & anti-aging product lines. Developed by founder Adrienne Denese, MD., Ph.D., this skin care company has a global customer base that numbers in the thousands; it  has recorded revenue over $500 million on QVC since 2003 and $18 million in 2019 alone. As QVC has been SSL’s only sales channel to date, the merger with Pressure BioSciences represents an opportunity for dramatic growth in sales.

On May 14, SSL announced it had developed a premium grade hand sanitizer that would allow the company to penetrate the fast-growing hand sanitizer market, expected to reach $5.5 billion by 2024 (http://ibn.fm/TeOH0). SSL continues to receive positive feedback for its product and has received significant interest from many large retailers.

Pressure BioSciences will acquire SSL through its planned acquisition of Cannaworx, Inc. Both companies offer PBIO a diverse portfolio of products and intellectual property developed by its founders Dr. Adrienne Denese and Dr. Bobby Ghalili, DMD.  These acquisitions by PBIO were announced on April 28, 2020 (http://ibn.fm/t7OWx). The merger of SSL, Cannaworx, Inc., and Pressure BioSciences is in the final stages, pending due diligence and acquisition financing, and is expected to close by June 30, 2020.

The resulting entity will operate under the name of Availa Bio, while each of the three companies will operate as separate, highly synergistic divisions under the Availa Bio umbrella. The new parent company will be publicly traded as a QB company on the OTC Marketplace.  Availa Bio will be led by CEO Jim Morrison, former President of L’Oreal, StarShop, and Graham Webb. Mr. Morrison is widely regarded as one of the top brand strategists in the global personal care industry.

The $3.5 million order announced on June 11 is merely the initial order for a four-month supply of the premium, dermatological hand sanitizer product. Mr. Morrison expects future orders and other substantial ongoing growth in the hand sanitizer product area. “Since the May 14 announcement that we were entering the multi-billion-dollar hand sanitizer market, I have taken the opportunity to discuss our new, premium grade hand sanitizer product with several large U.S. retail outlets. The reception we received was extremely positive,” he said.

Dr. Denese added that the new product is a direct response of the significant shortages of hand sanitizers reported by stores all over the U.S. over the past few months. “With SkinScience Labs’ nearly two decades of experience in formulation, manufacturing, and distribution, and my expertise and training as a scientist and physician, it became clear that we could become an important new part of the solution,” Dr. Denese explained. “With particular focus on the adverse effects that the high alcohol content in typical hand sanitizers have on skin, we went back to the lab and formulated a premium quality, dermatologically driven hand sanitizer.”

The Dr. Denese SkinScience product lines, as well as the Cannaworx product lines, will leverage Pressure BioSciences’ Ultra Shear Technology (UST) for preparing high quality nanoemulsions to drive product quality and effectiveness, while concomitantly reducing manufacturing costs. This will benefit both existing cosmetics formulations and future nutritional and therapeutic components.  It will also position SkinScience Labs as a leader in the rapidly emerging cosmeceuticals applications market.

The newly merged company will be off and running as soon as it is formed, as Availa Bio will own 31 patents, have hundreds of corporate and thousands of retail customers, and will have several hundred products on the market already generating revenue: SSL saw $18 million in 2019 revenue (without the hand sanitizer), and Pressure BioSciences saw approximately $2 million in 2019 revenue without the recently announced new order for an additional $2.4 million. Although Cannaworx had no products on the market in 2019, a new immune booster product will be launched in mid-July, followed by several other unique, hemp-derived, CBD infused products.  It is extremely exciting to think what the combination of these three companies will yield!

For more information, visit the company’s website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• Pew Research Center survey shows majority of public have experienced data breach; half don’t trust social media sites to protect personal data
• SRAX’s BIGtoken platform revolutionizes data collection
• Proprietary app allows users ability to choose what data to share, as well as who can buy that data and how it’s used

More than 60% of Americans have personally experienced a major data breach, and roughly half do not trust social media sites to protect their personal information (http://ibn.fm/ZrZ0k). These findings by Pew Research Center don’t surprise the data security experts at SRAX (NASDAQ: SRAX), a digital marketing company focused on providing consumer data-management services and pioneering technology that allows consumers to control their own information — and be compensated when they choose to share that information.

“Cyberattacks and data breaches are facts of life for government agencies, businesses and individuals alike in today’s digitized and networked world,” noted the Pew Center report. “This survey finds that a majority of Americans have directly experienced some form of data theft or fraud, that a sizeable share of the public thinks that their personal data have become less secure in recent years, and that many lack confidence in various institutions to keep their personal data safe from misuse.”

The leaders at SRAX not only recognized this compelling concern felt by the American public—they responded to it. The Company’s BIGtoken platform revolutionizes data collection. Available for download on the on the App Store and Google Play, the BIGtoken app provides consumers with a secure, transparent environment where they can own and earn from their data.

With more than 16.5 million users, BIGtoken offers its members the ability to choose what data they want to share, as well as who can buy that data and how it’s used. And when they opt in to share their data — anonymously — BIGtoken users receive cash or gift cards; they can even deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart. In addition, SRAX has partnered with several high-profile, nonprofit associations to allow BIGtoken users the option to donate their earnings.

And the BIGtoken app benefits companies as well. Advertisers and marketers that purchase access to anonymized segments of information from BIGtoken know that the data they receive is consumer verified and in compliance with the growing number of consumer privacy acts enacted not only in the United States but around the world.

The optimization and monetization of data is booming business. Studies show that global spending on big data and business analytics solutions is projected to reach $260 billion by 2022. SRAX is committed to providing tools for this space that deliver choice, transparency and compensation to the individual along with accurate and reliable information to businesses.

SRAX’s technology unlocks data for brands in the CPG, investor relations, luxury, and lifestyle verticals. Through its various platforms, SRAX is monetizing its data sets and growing multiple recurring revenue streams. In addition to BIGtoken, the Company offers Sequire, a premier platform for investor intelligence and communication. Through Sequire, public companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Obstructive Sleep Apnea (“OSA”) is a pervasive disorder impacting the lives of up to 1 billion people globally and approximately 54 million Americans. OSA has been linked to increased rates of cancer, hypertension, cardiovascular disease, ADHD, Alzheimer’s, diabetes, dementia, and ultimately—up to 10-year shorter lifespans.
• Current front-line treatment options such as CPAP are intrusive and must be used every night for life in order to be effective. Surgical options and implants can be risky and expensive.
• The Vivos System is the first treatment modality for mild to moderate OSA which has demonstrated the ability to remodel and enhance the size, shape, and function of the human airway—all within a relatively short time and without the need for lifetime intervention and treatment.

For chronic insomniacs and sleep apnea sufferers the world over, help has finally arrived. A revolutionary remedy developed by Vivos Therapeutics represents a possible solution to the frustrating and potentially life-threatening condition known as Obstructive Sleep Apnea (“OSA”). This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development—the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices.  Over the typical 18 to 24 month course of treatment, we believe the patient’s upper airway is remodeled and enhanced, thereby reducing the tissue obstructions that gave rise to the OSA.  Thus, Vivos technology represents the first true hope of an effective and lasting non-surgical OSA solution that in most cases, doesn’t require a lifetime of treatment intervention.  For the first time, the salutation “good night” will truly mean a good night for these sufferers.

Years ago, before we understood just how deadly and debilitating OSA truly was, many people actually poked fun at those who suffered from it.  Some erroneously still consider it to be a condition that only affects overweight middle-aged males.  Today, however, we know that patients of all ages, ethnicities, BMI scores, and demographics are at risk.  Even mild-to-moderate sufferers are known to be at much greater risk for virtually all of the major chronic diseases plaguing modern man—cancer, diabetes, hypertension, cardiovascular disease, stroke, Alzheimer’s, ADHD, dementia, fibromyalgia, and more.  The latest research has highlighted the key role that a good night’s rest plays in our overall health and wellness—both mentally and physically.  For those with OSA, it can be impossible to experience the rest and rejuvenation that comes from a good night’s rest.

The severity of OSA is typically measured by what is known as the Apnea Hypopnea Index or AHI.  Simply put, this index tallies up the number of times per hour during the night that the patient stops breathing for at least 10 seconds (an apnea).  Five time or less per hour is considered normal.  Between five and fifteen times is considered mild.  Between 15 and 30 is considered moderate, and 30 or more is considered severe.  Most patients think of snoring when they think of OSA.  The two conditions are related but different, and while almost all OSA patients snore, not all snorers have OSA.  Only a polysomnogram or home sleep test can tell for sure.  Those tests will measure a number of parameters that go on during sleep, and from that data an AHI score can be derived.

The latest diagnostic technology from SleepImage, which recently received FDA clearances, can actually detect and render a medical diagnosis for OSA via a single sensor device worn on the wrist.  The technology uses the latest advances in cardiopulmonary coupling to derive not only an AHI score, but also provide many other important indicators of sleep quality.  Given the fact that 80% or more of all patients believed to have OSA remain undiagnosed and untreated, the growing ability to screen and identify potential sufferers is creating more and more patients seeking treatment.  As this happens, Vivos Therapeutics is well positioned to be the treatment of choice.

The current medical “Gold Standard” for the non-surgical treatment of OSA is continuous positive airway pressure (or CPAP).  These systems consist of a machine that blows air through a tube connected to a face mask worn by the sleeper. They are generally effective at alleviating symptoms, but can be uncomfortable, poorly tolerated and obtrusive to use and maintain.  In addition, they can affect the quality of sleep of both sufferers and their partners.  In stark contrast, the Vivos System is simple to use and comfortable to wear.  It doesn’t make noise or affect the person laying next to the patient.  It doesn’t harbor mold or bacteria that can lead to respiratory infections and pneumonia.  Most patients report an improvement in their rest and overall energy levels within days or a few short weeks of treatment.

The remodeling and airway enhancement effects of the Vivos System are referred to as Pneumopedics(R).  Think of it like the three-dimensional expansion of a balloon when air is blown into it.  Pneumopedics is a natural process induced by the company’s proprietary biomimetic technology, which is believed to remodel airway tissues to increase their size, shape and capacity. The system was developed using expertise drawn from a number of medical and dental specialties, particularly dental practitioners who have completed advanced training in craniofacial sleep medicine. Unlike many other approaches, the Vivos System aims for a lasting resolution by targeting the root cause of obstructive sleep apnea: abnormal development of the craniofacial anatomy.

Central to the success of the company is its ability to recruit and train dentists in the proper integration of the Vivos System into their practices.  The company currently has over 1,350 trained providers throughout North America, with others scattered around the world.  The company regularly conducts online continuing education and other training broadcasts that expose this revolutionary technology to dentists and other healthcare providers on a global scale.  This year to date the company has presented at least some portion of its overall continuing education program on airway development and the central role of dentistry to over 47,000 clinicians and staff members worldwide.

For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS

• Pure Extracts is the development leader in the Canadian cannabis extract segment, which is valued by Deloitte at $2.7 billion annually.
• The Company is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.
• The psychedelic and functional mushroom industries are among the fastest growing in North America, with the global medicinal mushroom market expected to grow by $13.88 billion annually by 2024.
• Growing societal awareness and acceptance of mental illness as a legitimate disease have served as catalysts for a new search for innovative treatments and, as a result, interest in psychedelics.
• Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for the treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence.

Pure Extracts Corp., headquartered in Pemberton, British Columbia, is a private, plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extract is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts are available in the company’s newsroom at http://ibn.fm/Pure

• Numbers in streaming platform viewership have risen sharply due to COVID-19
• MVES’s economic solutions have made it competitive streaming option while similar businesses have faced financial challenges
• MVES’s innovative approach to streaming differentiates it from other studios

While COVID-19 has had detrimental effects on finances for the film industry and newly-emerging startups, The Movie Studio (OTC: MVES), an independent motion picture production company, has preserved its financial assets through strategic production planning and capitalizing on the surge in digital content consumption.

About 66% of global respondents watch some form of video on demand (“VOD”) programming; out of those respondents, 43% watch VOD programming at least once a day (http://ibn.fm/MkLk7). Furthermore, now that a substantial portion of the workforce has been furloughed at home and movie theaters remain closed for business, the demand for online streaming services has increased drastically.

In the dynamic market of over the top (“OTT”) programming, MVES ‘s business model is proving to be resourceful for the company. The Movie Studio Inc. distinguishes itself from other platforms in that it capitalizes on hiring lesser known actors and actresses in its original motion pictures. By creating films and distributing them on major subscription-based video on demand (“SVOD”) platforms without the expense of recognizable movie stars, MVES has the unique potential to increase production quality and reduce overall capital expenditures.

Episodic movie production is one strategy SVOD providers are using to innovate in the space. MVES’s production goal is to film movies in ten “chapters” and then edit them together to make a complete film. The chapters are then released via The Movie Studio’s App, which currently has 650,000 subscribers and is available for download in the App Store and Google Play. Similar to The Movie Studio’s “chapters,” Quibi (short for “quick bites”) is another OTT streaming platform that produces short-form movies and TV shows, with each episode being less than 10 minutes. However, Quibi has had some financial struggles, as “the advertisers, which include PepsiCo Inc., Yum Brands Inc.’s Taco Bell, Anheuser-Busch InBev SA BUD, and Walmart Inc. have asked for the changes because of concerns about the service’s low viewership or the impact of the coronavirus pandemic on their businesses” (http://ibn.fm/uG2Jd). Though staying afloat in the highly competitive OTT/VOD market can prove difficult, The Movie Studio’s unique strategy of minimizing capital production expenses historically associated with blockbuster film production positions it to potentially disrupt the evolving industry.

The Movie Studio Inc. has the advantage of being founded in 1961 with established experience in the motion picture industry. The vertically integrated company has an objective in developing, manufacturing, and distributing independent film content for worldwide consumption. MVES is the only major independent studio located in South Florida that manages its own in-house marketing and distribution department, and its unique revenue-oriented growth strategy positions it as a leading candidate to address the challenges within the field other competitors are struggling to alleviate.

Due to the fallout from the COVID-19 pandemic, the movie industry is changing. As citizens are limited in going out freely, visiting theaters to see the latest films, the industry is responding by bringing these options to the home TV screen.  Over the top cable services—Roku, Binge Networks, Hulu—are options with downloadable movies. How timely for them to be in this Video on Demand industry—allowing for a totally customizable experience. The most recent release that came out from DreamWorks Animation–Trolls—came out on demand. The world is shifting to an on-demand format, and The Movie Studio Inc. is poised to meet those demands.

For more information, visit the company’s website at www.TheMovieStudio.com

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES